Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 83
- Registration Number
- NCT00825734
- Locations
- 🇺🇸
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸Florida Cancer Specialists, Ft. Myers, Florida, United States
🇺🇸St. Louis Cancer Care, Chesterfield, Missouri, United States
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00821886
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸Mercy Hospital, Portland, Maine, United States
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 68
- Registration Number
- NCT00805961
- Locations
- 🇺🇸
Peninsula Cancer Institute, Newport News, Virginia, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 614
- Registration Number
- NCT00789581
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Mercy Hospital, Portland, Maine, United States
🇺🇸Kansas City Cancer Centers, Overland Park, Kansas, United States
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00759928
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 82
- Registration Number
- NCT00741988
- Locations
- 🇺🇸
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
🇺🇸Peninsula Cancer Institute, Newport News, Virginia, United States
🇺🇸Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
- Conditions
- Carcinoma
- Interventions
- Other: Treatment determined by physician
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 289
- Registration Number
- NCT00737243
- Locations
- 🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸Wellstar Cancer Research, Marietta, Georgia, United States
🇺🇸Integrated Community Oncology Network, Jacksonville, Florida, United States
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00731211
- Locations
- 🇺🇸
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸Baptist Hospital East, Louisville, Kentucky, United States
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT00695292
- Locations
- 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Florida Hospital Cancer Insitute, Orlando, Florida, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT00633594
- Locations
- 🇺🇸
Providence Medical Group, Terre Haute, Indiana, United States
🇺🇸RHHP/ Hope Cancer Center, Terre Haute, Indiana, United States
🇺🇸Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States